On a webcast, Compass Pathways management shared further insight into this morning’s Phase 3 program readout, which featured a first look at topline data from COMP006 and 26-week data from COMP005.
We covered that topline in depth, via in-house analysis and discussion with CEO Kabir Nath and CMO Guy Goodwin: Breaking: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Invites Debate. Since market open, shares in Compass have risen sharply, up over 30% at the time of writing.
Here, we share the slides from the webcast and commentary for those of you who want to dive even deeper.
In this Article
- Baseline Demographics
- COMP005 Efficacy: A Closer Look
- COMP006 Efficacy: A Closer Look
- Safety Profile: A Closer Look
- Commercial Update
- Q&A
Sign-in or join Pα+ to read this article…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓  Regular Bulletins covering key topics and trends in the psychedelics space
✓  Regular articles and deep dives across psychedelic research, policy and business
✓  Interviews with insiders
✓  Monthly interactive database and commentary on psychedelic patents
✓  Quick-take analysis of major developments
✓  A Library of primers and explainers
✓  Access to our full back catalogue
